1.
The Scottish Intercollegiate Guidelines Network website is at http://www.sign.ac.uk [Internet]. Available from: http://www.sign.ac.uk/
2.
The American Diabetes Association [Internet]. Available from: https://www.diabetes.org/
3.
The Cochrane collaboration at http://www.cochrane.org/ helps "healthcare practitioners, policy-makers, patients, their advocates and carers make well-informed decisions about health care, by preparing, updating, and promoting the accessibility of Cochrane Reviews.” [Internet]. Available from: http://www.cochrane.org/
4.
NHS Evidence, an offshoot of NICE, provides basic information on evidence-based management of many common conditions, including diabetes, and can be found at https://www.evidence.nhs.uk/ [Internet]. Available from: https://www.evidence.nhs.uk/
5.
The commercial but not-for-profit Trip database at http://www.tripdatabase.com claims to be "the internet’s premier source of evidence-based content” [Internet]. Available from: http://www.tripdatabase.com/
6.
The International Diabetes Federation (IDF) is at http://www.idf.org [Internet]. Available from: http://www.idf.org/
7.
The George Eliot Diabetes Care Team’s Alphabet Strategy website is at www.abcdiabetes.co.uk [Internet]. Available from: http://www.abcdiabetes.co.uk/
8.
The Critical Appraisal Skills Programme (CASP) critical appraisal checklists can be downloaded from http://www.casp-uk.net/ [Internet]. Available from: https://casp-uk.net/casp-tools-checklists/
9.
Essential Values-Based Practice is supported by a website jointly hosted by Cambridge University Press and Warwick Medical School at http://www.go.warwick.ac.uk/values-basedpractice [Internet]. Available from: http://valuesbasedpractice.org/
10.
The European Association for the Study of Diabetes (EASD) [Internet]. Available from: http://www.easd.org/
11.
Diabetes Care: 40 (Supplement 1). Diabetes Care [Internet]. 2017;40(Supplement 1). Available from: https://0-care-diabetesjournals-org.pugwash.lib.warwick.ac.uk/content/40/Supplement_1
12.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2015 Nov 26;373(22):2117–28. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1504720#t=article
13.
Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine [Internet]. 2017 Jun 8;376(23):2300–2. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMc1701990
14.
Effects of Liraglutide on Glycemic Control :Cleveland Clinic Journal of Medicine. 2015; Available from: http://www.mdedge.com/ccjm/clinical-edge/summary/obesity/effects-liraglutide-glycemic-control
15.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2017;(377):644–57. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1611925#t=article
16.
Nauck MA. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks. Diabetes Care [Internet]. 2013 Jul 1;36(7):2126–32. Available from: http://0-care.diabetesjournals.org.pugwash.lib.warwick.ac.uk/content/36/7/2126
17.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine [Internet]. 2013 Oct 3;369(14):1317–26. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1307684#t=article
18.
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient. JAMA [Internet]. 2016 Mar 8;315(10). Available from: http://0-jamanetwork.com.pugwash.lib.warwick.ac.uk/journals/jama/fullarticle/2499252
19.
Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, Kirsh S, Kullgren JT, Prenovost K, et al. Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia. JAMA Internal Medicine [Internet]. 2015 Oct 26; Available from: http://0-jamanetwork.com.pugwash.lib.warwick.ac.uk/journals/jamainternalmedicine/fullarticle/2466631
20.
Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society [Internet]. 2016;64(3):543–52. Available from: http://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/10.1111/jgs.14028/abstract
21.
Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. The Lancet Diabetes & Endocrinology [Internet]. 2015;3(7):503–4. Available from: http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S2213858715002260?via%3Dihub
22.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016 Jul 28;375(4):323–34. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1515920#t=article
23.
Scheen AJ. SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports [Internet]. 2016 Oct;16(10). Available from: https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s11892-016-0789-4
24.
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology [Internet]. 2015 Dec;14(1). Available from: https://0-cardiab-biomedcentral-com.pugwash.lib.warwick.ac.uk/articles/10.1186/s12933-015-0260-x
25.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet [Internet]. 2015 Dec; Available from: http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S0140673615012258
26.
Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research [Internet]. 2015;12(2):90–100. Available from: http://0-journals.sagepub.com.pugwash.lib.warwick.ac.uk/doi/10.1177/1479164114559852
27.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016;375(19):1834–44. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/10.1056/NEJMoa1607141#t=article
28.
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy [Internet]. 2016;17(12):1581–3. Available from: http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073
29.
Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care [Internet]. 2017 May;40(5):671–8. Available from: http://0-care.diabetesjournals.org.pugwash.lib.warwick.ac.uk/content/40/5/671
30.
Wu JHY, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology [Internet]. 2016 May;4(5):411–9. Available from: http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S2213858716000528
31.
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy [Internet]. 2016;17(12):1581–3. Available from: http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073
32.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016;375(19):1834–44. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1607141#t=article
33.
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Annals of Internal Medicine [Internet]. 2016;164(11). Available from: http://0-annals.org.pugwash.lib.warwick.ac.uk/aim/article/2513979/diabetes-medications-monotherapy-metformin-based-combination-therapy-type-2-diabetes
34.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2015;373(22):2117–28. Available from: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/10.1056/NEJMoa1504720
35.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine [Internet]. 2015;373(23):2247–57. Available from: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/2119957013/EA851E49618490DPQ/1?accountid=14888
36.
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective. Circulation [Internet]. 2017 Jul 18;136(3):249–59. Available from: https://0-www-ncbi-nlm-nih-gov.pugwash.lib.warwick.ac.uk/pubmed/28522450
37.
Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia [Internet]. 2018 Jan;61(1):58–65. Available from: https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4422-0
38.
Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Bartlett T, et al. Type 2 diabetes in child and adolescent. Pediatric Diabetes [Internet]. 2014;15:26–46. Available from: http://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/10.1111/pedi.12179/epdf
39.
Pediatric Diabetes. 15(S20). Available from: http://onlinelibrary.wiley.com/doi/10.1111/pedi.2014.15.issue-S20/issuetoc
40.
Bangstad HJ, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes [Internet]. 2009;10(6):82–99. Available from: http://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/10.1111/j.1399-5448.2009.00578.x/abstract
41.
ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber [Internet]. 2016; Available from: http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/
42.
ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber [Internet]. 2016; Available from: http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/
43.
Rang H. Pharmacokinetics. In: Rang & Dale’s pharmacology [Internet]. 7th ed. Edinburgh: Elsevier/Churchill Livingstone; 2012. p. 123–31. Available from: https://contentstore.cla.co.uk/secure/link?id=1d4bfbd8-c343-e611-80bd-0cc47a6bddeb
44.
Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia [Internet]. 2017 Aug;60(8):1385–9. Available from: https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4301-8
45.
Young LA, Buse JB, Weaver MA, Vu MB, Mitchell CM, Blakeney T, et al. Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. JAMA Internal Medicine [Internet]. 2017 Jul 1;177(7). Available from: https://0-jamanetwork-com.pugwash.lib.warwick.ac.uk/journals/jamainternalmedicine/article-abstract/2630691?redirect=true
46.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2008 Jun 12;358(24):2545–59. Available from: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223930983?accountid=14888
47.
Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease. Annals of Internal Medicine [Internet]. 2017 Feb 7;166(3). Available from: http://0-annals.org.pugwash.lib.warwick.ac.uk/aim/article-abstract/2595889/clinical-outcomes-metformin-use-populations-chronic-kidney-disease-congestive-heart?doi=10.7326%2fM16-1901
48.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2015;373(3):232–42. Available from: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1696912909?accountid=14888
49.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2017; Available from: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1931756550?accountid=14888
50.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine [Internet]. 2013 Oct 3;369(14):1317–26. Available from: https://0-www-nejm-org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1307684
51.
Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2008;358(6):580–91. Available from: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223923658?accountid=14888
52.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2015 Nov 26;373(22):2117–28. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1504720#t=article
53.
Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia [Internet]. 2016 Nov;59(11):2298–307. Available from: https://link.springer.com/article/10.1007/s00125-016-4065-6
54.
The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2008 Jun 12;358(24):2560–72. Available from: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223924651/fulltextPDF/4EC80B054DE144D4PQ/1?accountid=14888
55.
Chen L, Pei JH, Kuang J, Chen HM, Chen Z, Li ZW, et al. Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. Metabolism [Internet]. 2015 Feb;64(2):338–47. Available from: http://www.metabolismjournal.com/article/S0026-0495(14)00312-6/fulltext
56.
Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. The Lancet [Internet]. 2004 May;363(9421):1589–97. Available from: https://0-www-sciencedirect-com.pugwash.lib.warwick.ac.uk/science/article/pii/S0140673604162028
57.
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine [Internet]. 2008 Jun 12;358(24):2545–59. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa0802743#t=article
58.
Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The Lancet Diabetes & Endocrinology [Internet]. 2017 Nov;5(11):887–97. Available from: https://0-www-sciencedirect-com.pugwash.lib.warwick.ac.uk/science/article/abs/pii/S2213858717303170
59.
Complications of Diabetes Mellitus | InTechOpen [Internet]. Available from: https://www.intechopen.com/books/pathophysiology-and-complications-of-diabetes-mellitus
